Adherence rates with infliximab therapy in Crohn's disease
Article first published online: 12 SEP 2006
Alimentary Pharmacology & Therapeutics
Volume 24, Issue 7, pages 1099–1103, October 2006
How to Cite
KANE, S. and DIXON, L. (2006), Adherence rates with infliximab therapy in Crohn's disease. Alimentary Pharmacology & Therapeutics, 24: 1099–1103. doi: 10.1111/j.1365-2036.2006.03092.x
- Issue published online: 12 SEP 2006
- Article first published online: 12 SEP 2006
- Publication data Submitted 15 December 2005 First decision 17 January 2006 Resubmitted 13 July 2006 Accepted 14 July 2006
Background Inflammatory bowel disease is associated with non-adherence to treatment with oral medications.
Aim To assess the intravenous infliximab adherence rate and identify risk factors for non-adherence to treatment.
Methods Infliximab infusion dates for 1 June 2002–30 October 2003 were obtained. Additional information was obtained from two other administrative and patient-based databases. Non-adherence was defined as a ‘No Show’ designation for a scheduled appointment. Non-adherence rate, odds ratios for associations to ‘No Show’ appointments and analysis were performed to identify patient characteristics associated with non-adherent behaviour.
Results One thousand hundred and eighty-five infliximab infusions were scheduled for 274 patients. Forty-eight (4%) of appointments were classified as ‘No Show’. Six patients accounted for 13/48 (27%) of failed appointments; another 35 patients missed one appointment. ‘No Show’ appointments were more likely to be for female patients, those on concomitant immunomodulators and those >18 weeks from initial infusion. Patients who missed >1 appointment were more likely to be female and have Medicaid vs. those with only one missed appointment (P < 0.05). Indication, patient area code and race were not significantly associated with single or repeated No Show behaviour.
Conclusions Overall, the non-adherence rate for infliximab is low. Risk factors that may contribute to non-adherence to treatment include female gender and maintenance dosing.